Elaine Haynes is President and CEO of KaloCyte, Inc. where she oversees the company’s business operations and drives execution of technical development and funding strategies. KaloCyte is developing ErythroMer, a bio-inspired artificial red blood cell substitute for when stored blood is not an available option. She is a seasoned and resilient executive with over 30 years of healthcare leadership expertise and extensive experience with general management and commercial development of complex pharmaceuticals, controlled substances, radiopharmaceuticals, contrast media and medical devices, turnarounds, M&A and divestitures.
Elaine was previously with Mallinckrodt Pharmaceuticals for over 28 years. As VP Alliance Management and Divestitures, she led the divestitures of Mallinckrodt’s contrast media and nuclear imaging businesses, delivering nearly $1 billion in total transaction value. Prior roles include VP & General Manager where she led teams in North and South America, Global Marketing for Imaging, Marketing Director, Training Manager, and Nuclear Pharmacist.
She completed her executive MBA at Washington University in St. Louis and her BS in Pharmacy from St. Louis College of Pharmacy, where she currently serves on the Board of Trustees as Vice Chair. She was recognized as one of St. Louis Business Journal’s “25 Most Influential Women” in 2014.